Trastuzumab deruxtecan in metastatic HER2+ breast cancer

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

Comprehensive Clinical Study Report: A Sample slide deck (PPT)Подробнее

A new drug trastuzumab for advanced breast cancerПодробнее

Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer | Dr. Jitendra PahlajaniПодробнее

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer ParadigmПодробнее

Antibody-Drug Conjugates into the Management of HR+ and Triple-Negative Metastatic Breast CancerПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancerПодробнее

DESTINY-Breast12 Intracranial activity of TDXd in HER2-positive Patients with brain metastasesПодробнее

DESTINY-Breast06: determining HER2-(ultra)low status in HR+ mBCПодробнее

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast CancerПодробнее

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast CancerПодробнее

How to Treat Metastatic Non-Small Cell Lung Cancer w/o Targeted Mut in Front-line - Dr. PreeshagulПодробнее

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast CancerПодробнее

Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ PharmacologyПодробнее

Dr Bardia on Current Approaches to HER2+ Breast Cancer ManagementПодробнее

ENHERTU - what it is and how it works #breastcancerПодробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

Dr Davis on the Investigation of Neratinib + Trastuzumab Deruxtecan in Advanced HER2+ Solid TumorsПодробнее

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated w...Подробнее